¼¼°èÀÇ Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå : Á¦Ç°º°, ¸®µå À¯Çüº°, À¯Çüº°, Àü°³/¿¬°áº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ¿¹Ãø(-2032³â)
Diagnostic Electrocardiograph/ECG Market by Product (Resting ECG, Stress ECG, Mobile Cardiac Telemetry), Lead Type (Single-lead, 3, 5, 6 & 12-lead ECG Device), Type (Portable ECG Device, Wearable ECG Device), Connectivity - Global Forecast to 2032
»óǰÄÚµå : 1756515
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 374 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,814,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,155,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,220,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,767,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå ±Ô¸ð´Â 2025³â 91¾ï 9,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 151¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 7.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2024-2032³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2024-2032³â
°ËÅä ´ÜÀ§ ±Ý¾×(10¾ï ´Þ·¯)
ºÎ¹® Á¦Ç°º°, ¸®µå À¯Çüº°, À¯Çüº°, Àü°³/¿¬°áº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

´ç´¢º´ ¹× CVD¿Í °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÇÔ²² Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ ´ëÆøÀûÀÎ Áõ°¡´Â Áø´Ü¿ë ECG ½ÃÀåÀÇ ¼ö¿ä¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ÀÇ·áºñ Áõ°¡, °¢ Áö¿ªÀÇ ÀÇ·á ÀÎÇÁ¶ó °³¼±µµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Áø´Ü¿ë ECG ±â±âÀÇ ±â¼ú ¹ßÀü, Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã, À¯¸®ÇÑ »óȯ ÇÁ·¹ÀÓ¿öÅ©, Á¤ºÎ Áö¿ø Á¤Ã¥ µîÀº ½ÃÀåÀÇ ¿ªµ¿¼ºÀ» ´õ¿í °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ¿Í Áø´Ü¿ë ECG ¼Ö·ç¼ÇÀÇ Á¢±Ù¼º ¹× ±¸¸Å ÆíÀǼºÀ» °³¼±Çϱâ À§ÇÑ ³ë·Âµµ ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áø´Ü¿ë ECG ½ÃÀåÀº 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±Þ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº °ü»óµ¿¸ÆÁúȯ, ³úÁ¹Áß, ¸»Ãʵ¿¸ÆÁúȯ°ú °°Àº CVD ¹ßº´·üÀÇ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ÀÇ Á¶±â ¹× Áö¼ÓÀûÀÎ ½ÉÀå ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä¿Í ¿ø°Ý ȯÀÚ °ü¸®ÀÇ Áõ°¡ Ãß¼¼´Â ÀÌ·¯ÇÑ ¼ºÀå Ãß¼¼¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼ÒÇüÈ­, ¹«¼± ¿¬°á °­È­ µî ÃÖ±Ù ±â±â ±â¼úÀÇ ¹ßÀüÀº ÀÌ·¯ÇÑ ±â±â¸¦ º¸´Ù È¿À²ÀûÀ̰í, »ç¿ëÀÚ Áß½ÉÀûÀ̸ç, »ç¿ëÇϱ⠽±µµ·Ï ¸¸µé°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÁøÈ­¸¦ ÅëÇØ ±âÁ¸ ÀÓ»ó ȯ°æ°ú ¿ø°ÝÁö¿¡¼­µµ ½ÉÀå Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô µÇ¾î ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÇ·á ¼­ºñ½º¸¦ ÃÖÀûÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¸®µå À¯Çü¿¡ µû¶ó Áø´Ü¿ë ECG ½ÃÀåÀº 12 ¸®µå, 5 ¸®µå, 3 ¸®µå, 6 ¸®µå, ´ÜÀÏ ¸®µå ECG ±â±â·Î ±¸ºÐµÇ¸ç, 12 À¯µµ ECG ½Ã½ºÅÛÀº 12 °³ÀÇ Àü±Ø ¹èÄ¡¸¦ ÅëÇØ ½ÉÀåÀÇ Àü±âÀû Ȱµ¿À» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÏ¿© ´Ù°¢ÀûÀ¸·Î º¼ ¼ö Àֱ⠶§¹®¿¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ±â´ÉÀº ½É±Ù°æ»ö, º¹ÀâÇÑ ºÎÁ¤¸Æ, ÇãÇ÷¼º ½ÉÀåÁúȯ µî ´Ù¾çÇÑ CVDÀÇ Á¤È®ÇÑ Áø´ÜÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÀÓ»óÀÇ, ƯÈ÷ ÀÀ±Þ½Ç, ÁßȯÀÚ½Ç ¹× ½ÉÀ庴 Àü¹® Ŭ¸®´Ð¿¡¼­ Áß¿äÇÑ ÀÓ»óÀû ÀÇ»ç°áÁ¤°ú Àû½Ã¿¡ Ä¡·á °³ÀÔÀ» À§ÇØ 12À¯µµ ½ÉÀüµµ°¡ Á¦°øÇϴ dzºÎÇÑ µ¥ÀÌÅÍ¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹«¼± ¿¬°á ¹× ¿ø°ÝÀÇ·á Ç÷§Æû°úÀÇ ¿øÈ°ÇÑ ÅëÇÕÀ» Ư¡À¸·Î ÇÏ´Â ÈÞ´ë¿ë µðÁöÅÐ 12À¯µµ ½ÉÀüµµ ÀåÄ¡¿Í °°Àº ÃÖ±ÙÀÇ ±â¼ú ¹ßÀüÀº Áø´Ü ½ÉÀüµµÀÇ Àü¸Á¿¡¼­ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ Áß¿äÇÑ ¿ªÇÒÀ» ´õ¿í °ø°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

Àü°³/¿¬°á¿¡ µû¶ó Áø´Ü¿ë ECG ½ÃÀåÀº µ¶¸³Çü, PC ±â¹Ý, Ŭ¶ó¿ìµå ±â¹Ý ½ÉÀüµµ ±â±â·Î ±¸ºÐµË´Ï´Ù. µ¶¸³Çü ½ÉÀüµµ ±â±â°¡ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¢±ÙÀÌ ¿ëÀÌÇϰí Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ CVDsÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¹× ÀçÅÃÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼ÒÇü, °íÁ¤¹Ð, »ç¿ëÇϱ⠽¬¿î ±â±âÀÇ °³¹ßÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¶ÇÇÑ ¿¹¹æÀû °Ç°­ °ü¸®¸¦ °­È­Çϰí ÀüÅëÀûÀÎ ÀÓ»ó ȯ°æ ¹Û¿¡¼­ ½ÉÀå °Ç°­ »óŸ¦ ÀÚ°¡ ¸ð´ÏÅ͸µÇÏ´Â °ÍÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ºÎÁ¤¸Æ ¹× ±âŸ ½ÉÀå ÁúȯÀ» Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ µµ¿òÀÌ µÇ¾î º´¿ø ¹æ¹® ºóµµ¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ¿¹¹æÀû ½ÉÀå °Ç°­ °ü¸®¸¦ À§ÇÑ ºñ¿ë È¿À²ÀûÀÎ ¼±ÅÃÀÌ µÉ ¼ö ÀÖÀ¸¸ç, ¿ø°ÝÀÇ·á Ç÷§Æû ¹× ÀΰøÁö´É°ú ¿øÈ°ÇÏ°Ô ÅëÇյǾî Áø´Ü ´É·ÂÀ» °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼¼°è Áø´Ü¿ë ECG ½ÃÀåÀº 5°³ ÁÖ¿ä Áö¿ª(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«)À¸·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â Áø´Ü¿ë ECGÀÇ °¡Àå Å« Áö¿ª ½ÃÀåÀ̸ç, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì ½ÃÀå¿¡¼­ÀÇ ¿ìÀ§´Â ¸î °¡Áö »óÈ£ ¿¬°üµÈ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ù°, CVDÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â °øÁߺ¸°ÇÀÇ ½Ã±ÞÇÑ ¹®Á¦·Î ´ëµÎµÇ°í ÀÖ¾î °ü·Ã ÀÇ·á ¼­ºñ½º ¹× Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â ÀÌ·¯ÇÑ °Ç°­ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ ÀÇ·á ¹× ÀÚ¿øÀ» È¿À²ÀûÀ¸·Î Á¦°øÇÏ´Â °ß°íÇϰí Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶ó¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì Áö¿ª ÁֹεéÀº °¡Ã³ºÐ ¼ÒµæÀÌ ³ô¾Æ ¿¹¹æ ÀÇ·á ¹× Ã·´Ü Ä¡·á ¿É¼Ç°ú °°Àº °Ç°­ °ü·Ã ÅõÀÚ¿¡ ¿ì¼±ÀûÀ¸·Î ÅõÀÚÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÁ¦·ÂÀº Çõ½ÅÀûÀÎ ÀÇ·á ±â¼ú ¹× ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖÀ¸¸ç, ÀÌ Áö¿ª Àü¿ª¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü µµ±¸, Ä¡·á ¹æ¹ý, ȯÀÚ °ü¸® ½Ã½ºÅÛ µî ÀÇ·á ºÐ¾ßÀÇ Ã·´Ü ±â¼ú ¹ßÀüÀÌ ³Î¸® º¸±ÞµÇ¸é¼­ Àü¹ÝÀûÀÎ Ä¡·áÀÇ ÁúÀÌ Çâ»óµÇ°í CVD ȯÀÚÀÇ °Ç°­ °á°ú°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ºÏ¹Ì ½ÃÀå ¼ºÀå°ú ÇコÄÉ¾î ¼Ö·ç¼ÇÀÇ Áö¼ÓÀûÀÎ ÁøÈ­¸¦ À§ÇÑ °­·ÂÇÑ È¯°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ GE Healthcare, Baxter, OSI Systems¿Í °°Àº ¾÷°è ¼±µµ ±â¾÷ÀÇ ¿µÇâ·ÂÀº ÀÌ Áö¿ªÀÇ Áø´Ü¿ë ECG ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Á¦Ç°º°, ¸®µå À¯Çüº°, À¯Çüº°, Àü°³/¿¬°áº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå(Á¦Ç°º°)

Á¦7Àå Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå(¸®µå À¯Çüº°)

Á¦8Àå Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå(À¯Çüº°)

Á¦9Àå Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå(Àü°³/¿¬°áº°)

Á¦10Àå Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå(ÃÖÁ¾»ç¿ëÀÚº°)

Á¦11Àå Áø´Ü¿ë ½ÉÀü°è/ECG ½ÃÀå(Áö¿ªº°)

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global diagnostic electrocardiograph/ECG market is projected to reach USD 15.18 billion by 2032 from USD 9.19 billion in 2025, at a CAGR of 7.4% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2032
Base Year2024
Forecast Period2024-2032
Units ConsideredValue (USD billion)
SegmentsProduct, lead type, type, deployment/ connectivity, end user, and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The significant expansion of the geriatric demographic worldwide, coupled with the escalating prevalence of chronic conditions such as diabetes and CVDs, is poised to drive the demand for the diagnostic ECG market. Additionally, the increasing focus on preventive healthcare, coupled with rising healthcare expenditures and improvements in healthcare infrastructure across various regions, also facilitates market growth. Technological advancements in diagnostic ECG devices, the introduction of innovative products, and favorable reimbursement frameworks, along with supportive government policies, are further expected to enhance market dynamics. Investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of diagnostic ECG solutions are also likely to bolster market progression.

The diagnostic ECG devices segment is to grow at the highest CAGR during the forecast period.

The diagnostic ECG market is predominantly driven by devices, which command the largest market share in 2024. This surge is primarily attributed to the rising incidence of CVDs, including coronary artery disease, stroke, and peripheral artery disease. Furthermore, the demand for early and continuous cardiac monitoring among geriatric populations, along with the increasing trend toward remote patient management, significantly underpins this growth trajectory. Recent advancements in device technology, such as miniaturization and enhanced wireless connectivity, are rendering these instruments more efficient, user-centric, and accessible. This evolution enables the provision of cardiac care in both conventional clinical environments and remote settings, thereby improving patient outcomes and optimizing healthcare delivery.

The 12-lead ECG devices segment captured the largest market share, by lead type, in 2024.

Based on lead type, the diagnostic ECG market is segmented into 12, 5, 3, 6, and single lead ECG devices. The 12-lead ECG systems dominate the market due to their ability to deliver comprehensive analysis and a multi-faceted view of cardiac electrical activity through twelve electrode placements-this capability facilitates accurate diagnosis of a range of CVDs, including myocardial infarctions, complex arrhythmias, and ischemic heart disease. Clinicians, particularly in emergency departments, ICUs, and specialized cardiology clinics, heavily depend on the rich data provided by 12-lead ECGs for critical clinical decision-making and timely therapeutic interventions. Furthermore, recent technological advancements, such as portable digital 12-lead ECG devices featuring wireless connectivity and seamless integration with telemedicine platforms, have further solidified the essential role of these systems in the landscape of diagnostic ECG.

The standalone ECG devices segment commanded the largest market share, by deployment/connectivity in 2024.

Based on deployment/ connectivity, the diagnostic ECG market is segmented into standalone, PC-based, and cloud-based ECG devices. Standalone ECG devices accounted for the market share, driven by the rising global prevalence of CVDs that necessitate more accessible and continuous monitoring. The technological advancements have led to the development of compact, precise, and user-friendly devices, coupled with an increasing focus on remote patient monitoring and home-based care. This trend also enhances preventive health management and facilitates self-monitoring of cardiac health outside traditional clinical environments. These devices are instrumental in the early detection of arrhythmias and other cardiac conditions, thus reducing the frequency of hospital visits. They serve as cost-effective alternatives for proactive cardiac health management and can be seamlessly integrated with telemedicine platforms and artificial intelligence for enhanced diagnostic capabilities.

North America accounted for the largest regional share of the diagnostic ECG market in 2024.

The global diagnostic ECG market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for diagnostic ECG, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The significant predominance of the North American market can largely be attributed to several interrelated factors. Firstly, there is a rising incidence of CVDs, which has become a pressing public health concern and is driving demand for related healthcare services and products. This increase is further supported by a robust and well-established healthcare infrastructure that efficiently provides medical care and resources to address these health challenges. Additionally, the population in North America enjoys elevated disposable incomes, which allows individuals to prioritize spending on health-related investments, including preventive care and advanced treatment options. This financial capability also supports the adoption of innovative medical technologies and solutions, which are widely accessible throughout the region. The extensive availability of cutting-edge technological advancements in healthcare, including diagnostic tools, treatment modalities, and patient management systems, enhances the overall quality of care and improves health outcomes for patients with CVDs. Together, these factors create a strong environment for market growth and the ongoing evolution of healthcare solutions in North America. Furthermore, the influence of leading industry players such as GE Healthcare, Baxter, and OSI Systems, Inc. is expected to catalyze growth in the diagnostic ECG market within the region.

A breakdown of the primary participants referred to for this report is provided below:

The major players operating in the diagnostic ECG market are GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Baxter (US), FUKUDA DENSHI (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), NIHON KOHDEN CORPORATION (Japan), OSI Systems, Inc. (US), Bittium (Finland), iRhythm Technologies, Inc. (US), Lepu Medical Technology (Beijing) Co., Ltd. (China), Midmark Corporation (US), BPL Medical Technologies (India), SCHILLER (Switzerland), ACS Diagnostics (US), Allengers (India), and Bionet Co., Ltd. (South Korea).

Research Coverage

This report studies the diagnostic ECG market based on product, lead type, type, deployment/ connectivity, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights on the following points:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 DIAGNOSTIC ECG MARKET, BY PRODUCT

7 DIAGNOSTIC ECG MARKET, BY LEAD TYPE

8 DIAGNOSTIC ECG MARKET, BY TYPE

9 DIAGNOSTIC ECG MARKET, BY DEPLOYMENT/CONNECTIVITY

10 DIAGNOSTIC ECG MARKET, BY END USER

11 DIAGNOSTIC ECG MARKET, BY REGION

12 COMPETITIVE LANDSCAPE

13 COMPANY PROFILES

14 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â